How Medical Research Can Leverage AI Without Risking Personal Data

November 3, 2021 08:35:02

Artificial intelligence (“AI”) can be used to accelerate research and advance healthcare. It can also play a crucial role in conducting clinical trials and drug research. Using artificial intelligence to pool medical data helps save lives because AI surpasses humans in diagnosing conditions and choosing treatments. However, pooling medical data and centralizing it is unethical, given that it doesn’t align with patient privacy conditions. Centralizing data from millions of individuals also makes it vulnerable to misuse, breaches and hacks.

So, how can we yield the same benefits as pooling data without sharing patient data?

Sharing data is impossible, mainly because of privacy laws, but despite this hindrance, the need to share data continues to grow as the dependence on artificial intelligence in medicine increases.

In spite of this growing need, potentially revolutionary discoveries remain unavailable to the global research community because data is stored in single silos of pharmaceutical firms, hospitals, laboratories, insurers and GPs.

Now new approaches have made it possible to develop algorithms that fortify each other in their collective analysis, without having to exchange data. This has been achieved by calculating and sharing technical features that preserve the intellectual property of the underlying models and data, as well as patient privacy. This approach will allow researchers and companies to advance medicine while affording citizens their privacy.

Why is artificial intelligence the best option?

Feeding data to artificial intelligence models enhances their ability to save lives. AI will also help counter wasteful spending, which will save millions. For instance, in the United States, medical costs associated with cancer are estimated to be more than $207 billion annually. Given that immunotherapies often go for over $100,000, this should come as no surprise. While immunotherapies are effective, they can cause harmful side effects and don’t work in some patients.

Using AI to gather data will allow doctors to identify optimal treatments, which can increase patient quality of life and outcomes and prevent unnecessary medical costs and interventions. In addition to this, using artificial intelligence to connect data silos will accelerate medical progress significantly.

For instance, researchers can study the human genome at large scale using data from connected silos, which will allow them to discover new data on different diseases. This will not only offer additional information on individuals who may be at risk of these ailments but also enable the development of new therapies and drug targets.

However, for AI to be used without controversy, a lot will need to be done to ensure that no commercial interests or people’s privacy are harmed. Companies such as RYAH Group Inc. (CSE: RYAH) are already deploying AI platforms that are tailored to meet the needs of research undertaken by government agencies, academic institutions and private firms conducting clinical trials.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.